01:43 AM EST, 11/03/2026 (MT Newswires) -- Basilea Pharmaceutica (BSLN.SW) received a milestone payment of $37.5 million from license partner Pfizer (PFE.F) for sales in Europe of its antifungal Cresemba, or isavuconazole. The Switzerland-listed biopharmaceutical company noted on Tuesday that Cresemba's total in-market sales increased 25% year over year between July 2025 and June 2026 to $817 million.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.